D68.32Hemorrhagic disorder due to extrinsic circulating anticoagulants

D68.32 is the ICD-10-CM diagnosis code for hemorrhagic disorder due to extrinsic circulating anticoagulants. It belongs to category D68 (other coagulation defects), block D65-D69 (coagulation defects, purpura and other hemorrhagic conditions) and chapter 3 (diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within D68.3 (hemorrhagic disorder due to circulating anticoagulants), D68.32 is specifically for hemorrhagic disorder due to extrinsic circulating anticoagulants. Related codes cover intrinsic circulating anticoagulants, antibodies, or inhibitors (D68.31).

Use an additional code for adverse effect, if applicable, to identify drug (T45.515, T45.525).

As a secondary diagnosis it is a CC (complication or comorbidity), which can move an inpatient stay into the "with CC" MS-DRG of its family, unless the principal diagnosis excludes it.

In MS-DRG v44.0, it is part of the grouping logic for DRG 813 (Coagulation Disorders, relative weight 1.5257), in MDC 16 (Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.

Before ICD-10, this condition was coded in ICD-9-CM as 286.7 (acquired coagulation factor deficiency).